Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today its decision to proceed with Phase III ...

Shanghai Ark Biopharmaceutical Co., Ltd. ('ArkBio') today announced that the National Medical Products Administration (NMPA) ...

The move, announced in Lagos, positions Nigeria as a strategic base to drive Roche’s 10-Year Diagnostics Strategy for Afric ...

Data from the POLARGO trial potentially establishes a new standard of care for patients with R/R DLBCL ineligible for ...

Roche entered into a Licensing, Development, and Commercialisation agreement with Prothena in December 2013 to develop and ...

During a live event, Ahmad Tarhini, MD, PhD, and participants discussed how to use combination immunotherapy in patients with ...

In a multicenter Phase III trial spanning eight leading clinical hospitals in China, Azstarys demonstrated statistically significant improvements over placebo in primary and secondary efficacy ...